Company profile MCRB

Seres Therapeutics Inc
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the mic...robiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/. Show More
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics near me to provide analysis

Correlation between past revenue and Seres Therapeutics near me search interest

There is not enough data for Seres Therapeutics near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 04:44:53.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Seres Therapeutics stock expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
20199
28
211.1% QoQ
13
-53.6% QoQ
28
115.4% QoQ
2020 10
11.1% YoY -64.3% QoQ
16
-42.9% YoY 60.0% QoQ
194
1392.3% YoY 1112.5% QoQ
94
235.7% YoY -51.5% QoQ
2021 59
490.0% YoY -37.2% QoQ
70
337.5% YoY 18.6% QoQ
51
-73.7% YoY -27.1% QoQ
67
-28.7% YoY 31.4% QoQ
2022 59
0.0% YoY -11.9% QoQ
41
-41.4% YoY -30.5% QoQ
55
7.8% YoY 34.1% QoQ
78
16.4% YoY 41.8% QoQ
2023 58
-1.7% YoY -25.6% QoQ
114
178.0% YoY 96.6% QoQ
30
-45.5% YoY -73.7% QoQ
95
21.8% YoY 216.7% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Seres Therapeutics stock search interestLast update: February 09 2024 04:44:53.
Correlation coefficient between keyword and revenue is 0.17
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 04:44:54.

The average 5 years interest of Seres Therapeutics stock was 4.48 per week.
The last year interest of Seres Therapeutics stock compared to the last 5 years has changed by 14.51%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 220.62%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics login to provide analysis

Correlation between past revenue and Seres Therapeutics login search interest

There is not enough data for Seres Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 04:44:59.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Seres Therapeutics news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201924
57
137.5% QoQ
0
-100.0% QoQ
134
inf% QoQ
2020 18
-25.0% YoY -86.6% QoQ
77
35.1% YoY 327.8% QoQ
159
inf% YoY 106.5% QoQ
82
-38.8% YoY -48.4% QoQ
2021 45
150.0% YoY -45.1% QoQ
46
-40.3% YoY 2.2% QoQ
111
-30.2% YoY 141.3% QoQ
105
28.0% YoY -5.4% QoQ
2022 20
-55.6% YoY -81.0% QoQ
176
282.6% YoY 780.0% QoQ
127
14.4% YoY -27.8% QoQ
59
-43.8% YoY -53.5% QoQ
2023 153
665.0% YoY 159.3% QoQ
132
-25.0% YoY -13.7% QoQ
48
-62.2% YoY -63.6% QoQ
95
61.0% YoY 97.9% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Seres Therapeutics news search interestLast update: February 09 2024 04:44:59.
Correlation coefficient between keyword and revenue is 0.21
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 04:45:00.

The average 5 years interest of Seres Therapeutics news was 6.39 per week.
The last year interest of Seres Therapeutics news compared to the last 5 years has changed by -17.21%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 28.09%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics CEO to provide analysis

Correlation between past revenue and Seres Therapeutics CEO search interest

There is not enough data for Seres Therapeutics CEO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics CEO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics SEC filings to provide analysis

Correlation between past revenue and Seres Therapeutics SEC filings search interest

There is not enough data for Seres Therapeutics SEC filings to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics SEC filings to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics clinical trials to provide analysis

Correlation between past revenue and Seres Therapeutics clinical trials search interest

There is not enough data for Seres Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics pipeline to provide analysis

Correlation between past revenue and Seres Therapeutics pipeline search interest

There is not enough data for Seres Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Seres Therapeutics microbiome therapie to provide analysis

Correlation between past revenue and Seres Therapeutics microbiome therapie search interest

There is not enough data for Seres Therapeutics microbiome therapie to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Seres Therapeutics microbiome therapie to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for MCRB
Earnings date: 2024-03-06 After close
Company name: Seres Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-15T04:00:00-07:00

GlobeNewswire
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

2026-09-08T15:00:00-07:00

GlobeNewswire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-09-01T04:00:00-07:00

GlobeNewswire
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

2026-08-05T04:00:00-07:00

GlobeNewswire
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

2026-07-08T08:30:00-04:00

Earnings Call Transcripts
Results of IST of SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) - Seres Therapeutics

2026-07-08T04:00:00-07:00

GlobeNewswire
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

2026-06-25T04:00:00-07:00

GlobeNewswire
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

2026-06-23T13:47:01.213520716Z

Analyst Upgrades
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

2026-06-23T11:29:15.215719332Z

Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

2026-06-05T11:00:00Z

GlobeNewswire
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

2026-05-12T11:00:00Z

GlobeNewswire
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-05T11:00:00Z

GlobeNewswire
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

2026-05-04T11:00:00Z

GlobeNewswire
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

2026-04-20T11:00:00Z

GlobeNewswire
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

2026-04-09T11:00:00Z

GlobeNewswire
Seres Therapeutics to Present at CARB-X Investor Day